Guggenheim Sticks With Buy on Humana Ahead of Q4 2025 Results
Guggenheim has reaffirmed a Buy rating and a $312 price objective on Humana (HUM) in advance of the insurer’s fourth-quarter 2025 results. The research house flagged a potentially turbulent market response when earnings arrive, driven largely by uncertain Medicare Advantage enrollment trends and profit dynamics that could shape 2026 guidance. Despi…